(Q43791704)

English

Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial

scientific article published in September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Michael Krainer

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

W J Köstler

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

T Brodowicz

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Y Attems

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

M Hejna

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

S Tomek

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

G Amann

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

W C Fiebiger

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

C H Wiltschke

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

C C Zielinski

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1281-1288

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: a study of the Spanish Group for Research on Sarcomas (GEIS)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel in patients with soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel (Taxol) plus doxorubicin plus filgrastim in advanced sarcoma: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012272007146

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1012272007146

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43791704&oldid=2103366528"